POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy

Clin Transl Med. 2021 Sep;11(9):e524. doi: 10.1002/ctm2.524.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Polymerase II / genetics*
  • DNA Polymerase III / genetics*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Mutation / genetics*
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / mortality
  • Neoplasms* / pathology
  • Poly-ADP-Ribose Binding Proteins / genetics*
  • Protein Domains / genetics
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors
  • Poly-ADP-Ribose Binding Proteins
  • POLD1 protein, human
  • DNA Polymerase II
  • DNA Polymerase III
  • POLE protein, human